secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2026-08-05T20:03:26+00:00
Accession:  0001193125-26-335016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q2 2026 revenue $109.4M (+43% YoY); Afrezza pediatric and Furoscix ReadyFlow approved
--------------------------------------------------------------------------------

- Q2 total revenue $109.4M, up 43% YoY; Furoscix contributed $22.2M in net sales.
- Afrezza net sales $17.0M (-7% YoY); pediatric indication approved May 29, early launch momentum.
- Furoscix ReadyFlow autoinjector approved July 23; commercial launch expected late August.
- Positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF; global Phase 2 enrolling.
- Closed $50M private placement to fund $45M CVR payment from Furoscix ReadyFlow approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/0001193125-26-335016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer